Actinium Pharmaceuticals, Inc. (ATNM)
After hours:
| Previous Close | 5.30 |
| Open | 5.35 |
| Bid | 5.03 x 1000 |
| Ask | 5.73 x 1100 |
| Day's Range | 5.19 - 5.44 |
| 52 Week Range | 4.00 - 14.70 |
| Volume | |
| Avg. Volume | 195,141 |
| Market Cap | 145.839M |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.93 |
| Earnings Date | Nov 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.17 |
PR NewswireActinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023. These include an oral presentation and two poster presentations detailing results from the completed and positive Phas
- PR Newswire
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced data was presented at Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting on Saturday, November 4, 2023, further supporting Actimab-A, the Company's clinical stage targeted radiotherapeutic comprised of the CD33 targeting antibody lintuzumab and the Actinium-225 (Ac-225) alpha-particle emitting payload.
- PR Newswire
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany.
